Illustrative image.
FEIBA
Anti‑inhibitor Coagulant Complex
$1480.00
1000IU · 1
BrandBranded medicine· By Takeda
Choose a pack
- Selected pack
Packs in this delivery
Test mode: no payment is taken. View cart
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
FDA boxed warningEmbolic and thrombotic events
Thromboembolic events have been reported during postmarketing surveillance following infusion of FEIBA, particularly following the administration of high doses and/or in patients with thrombotic risk factors.
Monitor patients receiving FEIBA for signs and symptoms of thromboembolic events.
Thromboembolic events have been reported during postmarketing surveillance, particularly following the administration of high doses and/or in patients with thrombotic risk factors.
About FEIBA
Overview
FEIBA (Anti-inhibitor Coagulant Complex) is a medicine made from human plasma. It is used in people with hemophilia A or B who have inhibitors to control and prevent bleeding, manage bleeding around surgery, and prevent or reduce bleeding episodes through routine preventive treatment. Its clotting factors help increase the production of thrombin, a substance involved in blood clotting, although its exact mechanism is not fully understood.
What it treats
For patients with hemophilia A or B who have inhibitors: - Control and prevention of bleeding episodes. - Management of bleeding around surgery. - Routine preventive treatment to prevent bleeding episodes or reduce how often they occur. FEIBA is not indicated for bleeding due to clotting factor deficiencies without inhibitors to factor VIII or factor IX.
Safety information
Side effects
Commonly reported side effects include anemia (low red blood cell count), diarrhea, bleeding into joints, nausea and vomiting. A positive test for hepatitis B surface antibodies was also commonly reported. Contact a doctor immediately for serious reactions, including severe allergic reactions or anaphylaxis, and blood clots that can cause stroke, pulmonary embolism (a clot in the lungs) or deep vein thrombosis (a clot in a deep vein). If symptoms of an allergic reaction occur, treatment with FEIBA must be stopped and appropriate treatment given. FEIBA is made from human plasma and may contain infectious agents, including viruses and the agent that causes variant Creutzfeldt-Jakob disease (vCJD). There is also a theoretical risk of transmission of the Creutzfeldt-Jakob disease (CJD) agent.
FDA boxed warning
Embolic and thrombotic events
Thromboembolic events have been reported during postmarketing surveillance following infusion of FEIBA, particularly following the administration of high doses and/or in patients with thrombotic risk factors.
Monitor patients receiving FEIBA for signs and symptoms of thromboembolic events.
Thromboembolic events have been reported during postmarketing surveillance, particularly following the administration of high doses and/or in patients with thrombotic risk factors.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
Do not use FEIBA if you have had anaphylaxis or a severe allergic reaction to FEIBA or any of its components, including factors of the kinin-generating system. It must not be used if you have disseminated intravascular coagulation (DIC), a condition involving widespread blood clotting, or an acute blood clot or blocked blood vessel, including a heart attack. FEIBA can cause blood clots, particularly at high doses or in people with risk factors for clotting. Patients receiving FEIBA should be monitored for signs and symptoms of blood clots. Severe allergic reactions, including anaphylaxis, may occur; treatment must be stopped and appropriate care given if symptoms develop. FEIBA is made from human plasma and may contain infectious agents, including viruses and the agent that causes variant Creutzfeldt-Jakob disease (vCJD). Transmission of the Creutzfeldt-Jakob disease (CJD) agent is theoretically possible.
Interactions
Tell your doctor if you use tranexamic acid or aminocaproic acid, medicines that help prevent blood clots from breaking down. Using these medicines with FEIBA may increase the risk of blood clots. Their use within approximately 6 to 12 hours after FEIBA is not recommended.
Using FEIBA
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label FEIBA (ANTI-INHIBITOR COAGULANT COMPLEX) KIT [TAKEDA PHARMACEUTICALS AMERICA, INC.] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
NovoEight
Antihemophilic Factor (recombinant)
By Novo Nordisk
Pack · from 1 per pack
Also for blood disorders
Brand $1,034.00
Koāte‑DVI
Antihemophilic Factor (human) (factor Viii)
By Grifols
Vial · from 1 per pack
Also for blood disorders
Brand $1,034.00
RhoGAM
Anti‑d (rh₀) Immunoglobulin (human)
By Kamada
Vial · from 1 per pack
Also for blood disorders
Brand $150.00
Ferriprox
Deferiprone
By None
Tablets · from 100 per pack
Also for blood disorders
Brand $377.00